ArticleVaccines2024

First-in-Human Phase I Trial to Assess the Safety and Immunogenicity of an Orf Virus-Based COVID-19 Vaccine Booster.

Meral Esen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.